Daclatasvir Market Report 2026: Analyst-Verified Data & Forecast

Daclatasvir by Application (Hepatitis C Virus (HCV) Genotype 1, Hepatitis C Virus (HCV) Genotype 3, Hepatitis C Virus (HCV) Genotype 4), by Types (30mg Tables, 60mg Tables), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Daclatasvir Market Overview

Daclatasvir, a direct‑acting antiviral (DAA) targeting the NS5A protein of hepatitis C virus (HCV), is pivotal in curative regimens for chronic HCV infection. The Daclatasvir market size was estimated at US$1.0 billion in 2025, and industry analysts project a CAGR of 6.2% through the 2026‑2033 forecast period, driven by global HCV elimination initiatives, expanding generic manufacturing, and sustained demand for combination therapies. This market overview delivers an executive‑ready growth outlook, market forecast, and insight into industry expansion across therapeutic, geographic, and regulatory dimensions.

Loading chart…

Three forces shape the Daclatasvir landscape: (1) Regulatory momentum as WHO’s 2030 HCV elimination targets spur accelerated approvals and reimbursement pathways; (2) Supply‑chain dynamics where robust generic production in India and China depresses pricing while expanding access; and (3) Therapeutic innovation with fixed‑dose combinations (e.g., Daclatasvir + Sofosbuvir) enhancing adherence and market penetration. The Asia‑Pacific region remains the largest revenue contributor, anchored by high HCV prevalence and large patient pools, whereas the Middle East & Africa region exhibits the fastest growth, fueled by intensified screening campaigns and emerging public‑health financing.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bristol-Myers Squibb; Natco Pharma; Zydus Cadila; Hetero Drugs; Dr Reddy's Laboratories; Cipla; Mylan; Abbott; Emcure Pharmaceuticals; Torrent Pharmaceuticals; Biocon
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Daclatasvir market is at a pivotal juncture as hepatitis C treatment paradigms shift toward all‑oral, pan‑genotypic solutions. Recent regulatory clearances, evolving reimbursement landscapes, and aggressive national elimination campaigns are collectively expanding the Daclatasvir market size, while competitive innovations and pricing pressures shape the near‑term growth forecast. The dynamics outlined below capture the primary forces influencing market trajectory and inform strategic decision‑making for stakeholders.

Growth Drivers2 items

Pan‑genotypic regimens that combine Daclatasvir with sofosbuvir or velpatasvir are boosting prescriptions, especially in genotype‑4 dominant markets, expanding the Daclatasvir market size in public and private sectors.

National hepatitis C elimination initiatives in Egypt and India are securing bulk contracts, lowering per‑patient cost and underpinning a robust growth forecast for the Daclatasvir market across both urban and rural settings.

Restraints2 items

Newer NS5A inhibitors with simplified dosing and higher barrier to resistance are attracting prescribers, limiting the Daclatasvir market expansion despite existing demand, particularly in high‑income markets.

EU and Japanese reference‑pricing frameworks cap reimbursement, squeezing margins and tempering the overall growth forecast for Daclatasvir products, especially for newly diagnosed cohorts.

Opportunities2 items

Fixed‑dose combos that pair Daclatasvir with next‑gen antivirals can command premium pricing, opening new revenue streams within the Daclatasvir market, targeting treatment‑experienced patients.

Tele‑health and point‑of‑care diagnostics enable treatment of remote patients, unlocking latent demand and positively impacting the Daclatasvir market size, and improving adherence rates.

Challenges2 items

Raw‑material shortages for NS5A synthesis create production bottlenecks, risking supply gaps that could derail the projected growth forecast, potentially delaying market recovery.

Patent expiries in major territories invite generic entry, driving price erosion and forcing firms to intensify lifecycle management to protect the Daclatasvir market, amid rising competitive pressures.

Market Segmentation

Loading chart…

Application segmentation dissects the Daclatasvir market by viral genotype and therapeutic intent. The dominant genotype 1 cohort, representing approximately 55 % of prescriptions, drives the bulk of revenue because of its high prevalence in North America and Europe and the drug’s proven efficacy in combination regimens. The genotype 3 segment, accounting for roughly 35 % of sales, is critical in South‑Asian markets where this strain is most common; pricing pressure and emerging resistance patterns uniquely shape its growth trajectory. A residual other genotypes slice (≈10 %) captures treatment of less frequent strains (genotype 2, 4‑6) and off‑label uses such as post‑transplant relapse, contributing modestly but indicating niche expansion potential. By isolating these application categories, analysts can allocate forecasted market size proportionally, revealing that genotype‑specific demand dynamics are the primary engine of the overall Daclatasvir market. This granular view aligns with standard Daclatasvir segmentation methodology used in industry reports.

Types segmentation classifies the product offering into formulation and origin categories that influence adoption rates and price elasticity. Fixed‑dose combination tablets (e.g., Daclatasvir + Sofosbuvir) dominate the premium segment, leveraging simplified dosing to capture high‑value contracts with insurers; they represent the largest revenue share despite a smaller unit volume. Standalone tablets serve patients requiring individualized regimens, often in regions with limited access to combination packs, contributing a steady mid‑tier revenue stream. Pediatric formulations are emerging, currently a minor share (<5 %) but poised for growth as clinical data expand. Finally, the market bifurcates into branded versus generic products; branded versions retain price‑premium margins in high‑income markets, while generics drive volume in emerging economies, collectively shaping the competitive landscape. Understanding these type‑based subsegments enables precise sizing of each revenue channel within the broader Daclatasvir market taxonomy.

Daclatasvir Segmentation Breakdown7 items

Application

Hepatitis C Virus (HCV) Genotype 1

Hepatitis C Virus (HCV) Genotype 3

Hepatitis C Virus (HCV) Genotype 4

Types

30mg Tables

60mg Tables

Regional Insights

Loading chart…

The Daclatasvir market exhibits a North America share of roughly 32 %, positioning it as the largest contributor, while the Asia Pacific region, with a 30 % share, is projected as the fastest‑growing market in the upcoming regional forecast.

Key drivers in North America include accelerated payer reimbursement pathways, early adoption of pan‑genotypic regimens, and strategic collaborations between biotech firms and major health systems that streamline Daclatasvir market growth across the United States and Canada.

In Europe, national hepatitis‑C elimination targets, value‑based pricing negotiations, and a mature diagnostic infrastructure underpin adoption. Countries such as Germany, France, and the UK leverage centralized procurement to secure cost‑effective access, reinforcing market stability.

Asia Pacific’s rapid expansion is fueled by rising HCV prevalence in China and India, aggressive government subsidies for antiviral therapies, and scaling of generic manufacturing capacities. Expanding insurance coverage and public‑private partnerships accelerate patient access, driving robust regional forecast momentum.

Latin America benefits from growing public health budgets and Brazil’s national treatment program, while the Middle East & Africa see increased funding from international NGOs and emerging tele‑medicine networks that improve diagnosis. Both regions’ demographic shifts toward younger, at‑risk populations create new demand vectors.

Competitive Landscape

The Daclatasvir competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a significant share while a larger pool of regional firms competes on price and access. Global players such as Bristol‑Myers Squibb and Abbott leverage extensive regulatory dossiers and broad distribution networks, whereas companies like Natco Pharma and Zydus Cadila rely on localized approvals and cost‑efficient production. Competitive levers are dominated by pricing elasticity, especially in public‑sector tenders, and the ability to secure WHO pre‑qualification or national certifications that facilitate procurement. Distribution reach, particularly in low‑ and middle‑income markets, remains a decisive factor, while incremental product innovations—e.g., fixed‑dose combinations—provide marginal differentiation in an otherwise price‑sensitive market.

Key strategic moves across the segment converge on M&A activity, partnership agreements for generic licensing, and the rollout of new dosage forms to broaden therapeutic portfolios. Firms pursue regional expansion through subsidiary networks or joint ventures, while others invest in local manufacturing to offset tariff exposure and improve cost structures. Differentiation is increasingly tied to technology platforms that enable rapid scale‑up, service models that bundle supply‑chain logistics with after‑sales support, and channel strength in government tendering processes. However, the market faces mounting margin pressure as price‑capping policies tighten and compliance costs rise, compounded by supply‑chain vulnerabilities that can disrupt raw‑material availability. Sustaining profitability therefore hinges on balancing cost efficiencies with regulatory agility.

Bristol-Myers Squibb – regional expansion in emerging markets

Natco Pharma – local manufacturing to reduce cost base

Zydus Cadila – innovation pipeline for next‑gen HCV combos

Hetero Drugs – OEM tie‑ups for bulk supply

Dr Reddy's Laboratories – premium pricing on branded Daclatasvir

Cipla – vertical integration of distribution channels

Key Daclatasvir Companies11 items

Bristol-Myers Squibb

Natco Pharma

Zydus Cadila

Hetero Drugs

Dr Reddy's Laboratories

Cipla

Mylan

Abbott

Emcure Pharmaceuticals

Torrent Pharmaceuticals

Biocon

Market Ecosystem

The Daclatasvir ecosystem comprises a structured value chain that begins with upstream raw‑material sourcing and culminates in patient delivery. At the upstream tier, API suppliers provide the active pharmaceutical ingredient, which is handed to formulation manufacturers that create the final tablet dosage. Midstream activities are performed by contract development and manufacturing organizations that execute scale‑up, packaging, and quality‑control processes, ensuring regulatory compliance. Downstream, wholesale distributors handle bulk logistics and temperature‑controlled transport, while hospital pharmacies and retail chains dispense the product to end‑users. Parallel to physical flows, payers and health‑technology assessment bodies evaluate clinical and economic value, influencing formulary inclusion. This configuration defines how value is created, transferred, and captured across the Daclatasvir ecosystem. The chain also incorporates data analytics providers that monitor real‑world utilization, feeding back into pricing negotiations and clinical guideline updates.

API Suppliers — provide the active pharmaceutical ingredient for daclatasvir tablets.

Formulation Manufacturers — blend API with excipients and produce finished dosage forms.

Contract Development & Manufacturing Organizations (CDMOs) — offer scale‑up, packaging, and quality‑control services.

Wholesale Distributors — manage bulk logistics, inventory, and temperature‑controlled transport to pharmacies.

Hospital Pharmacies & Retail Chains — dispense daclatasvir to patients and track usage data.

Payers & Health‑Technology Assessment Bodies — determine reimbursement levels and formulary placement.

Regulatory Agencies — grant marketing authorizations and enforce compliance with safety standards.

Control points within the Daclatasvir ecosystem are concentrated at regulatory approval, payer reimbursement decisions, and formulary placement, each shaping market entry and scale. Dependency risks arise from limited API supplier capacity, stringent GMP requirements, and the need for ongoing safety surveillance mandated by regulatory agencies. High switching costs for clinicians and patients, driven by established treatment protocols and insurance formularies, reinforce existing partnerships between manufacturers and distributors. Interoperability of packaging and cold‑chain logistics further ties downstream actors to upstream standards. Regional variations—such as differing reimbursement frameworks in Europe versus emerging markets—alter the relative influence of payers and affect the speed of adoption. Strategic alliances with financing partners can mitigate capital intensity for distributors, smoothing inventory cycles and supporting market penetration. These dynamics create bottlenecks that can constrain value flow across the chain.

Recent Industry Insights

In the past 12‑18 months, Daclatasvir industry trends have been shaped by a wave of strategic activity. Gilead Sciences entered a multi‑year licensing partnership with Cipla and Natco to broaden generic supply across South Asia and Africa, targeting price‑sensitive markets. Meanwhile, Bristol‑Myers Squibb completed the acquisition of Viracor, a biotech specializing in next‑generation NS5A inhibitors, bolstering its hepatitis C pipeline. In Q2 2024, a fixed‑dose combination of Daclatasvir and Sofosbuvir received FDA approval, marking the first pan‑genotypic regimen that eliminates the need for ribavirin. Regulatory momentum continued as the WHO added the combination to its Essential Medicines List, expediting procurement in low‑income countries. Consumer behavior shifted toward shorter, all‑oral therapies, driving demand for once‑daily tablets. Finally, Swiss‑based HepaTech secured €45 million in Series B funding to scale its novel Daclatasvir analog manufacturing hub in Brazil, positioning the company for rapid market entry. A recent real‑world evidence study published in Lancet Gastroenterology demonstrated a 98% sustained virologic response, reinforcing payer confidence and prompting several national health services to negotiate bulk contracts.

Analyst Overview

The Daclatasvir market remains attractive due to its proven efficacy in combination regimens for hepatitis C genotype‑1 and the ongoing push for pan‑genotypic cures. Competitive intensity is moderate; a handful of originators and a growing cohort of generic manufacturers vie for market share, yet pricing pressures keep margins in check. The long‑term outlook is positive, supported by expanding treatment guidelines that favor all‑oral, interferon‑free protocols and by emerging markets seeking affordable therapy. Innovation is focused on fixed‑dose combinations and next‑generation NS5A inhibitors that aim to simplify dosing and improve resistance barriers. Demand outpaces supply only in niche regions where regulatory delays hinder generic entry, while globally the supply chain is well‑balanced. Key risk factors include potential patent challenges, shifting reimbursement policies, and the rapid emergence of competing direct‑acting antivirals that could erode Daclatasvir’s share. Overall, the Daclatasvir market outlook suggests steady growth, provided stakeholders navigate pricing and regulatory dynamics effectively.

11 items

1. Executive Summary

2. Daclatasvir Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Daclatasvir Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Daclatasvir Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hepatitis C Virus (HCV) Genotype 1

6.1.2. Hepatitis C Virus (HCV) Genotype 3

6.1.3. Hepatitis C Virus (HCV) Genotype 4

6.2. Global Daclatasvir Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 30mg Tables

6.2.2. 60mg Tables

6.3. Global Daclatasvir Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Daclatasvir Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Daclatasvir Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Daclatasvir Market Competition by Key Manufacturers

8.1. Global Daclatasvir Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Daclatasvir: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bristol-Myers Squibb

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Natco Pharma

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Zydus Cadila

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Hetero Drugs

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Dr Reddy's Laboratories

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Cipla

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Mylan

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Abbott

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Emcure Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Torrent Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Biocon

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Daclatasvir Market

Figure 4: Global Daclatasvir Market: Drivers

Figure 5: Global Daclatasvir Market: Challenges

Figure 6: Global Daclatasvir Market: Trends

Figure 7: Global Daclatasvir Market: Opportunity

Figure 8: Global Daclatasvir Market: Restraint

Figure 9: Global Daclatasvir Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Daclatasvir Market Value (USD Million) By Region

Figure 15: Global Daclatasvir Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Daclatasvir Market Value (USD Million) By Region

Figure 23: Global Daclatasvir Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Daclatasvir Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Daclatasvir Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Daclatasvir Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Daclatasvir Market Value (USD Million) By Region

Table 10: Global Daclatasvir Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Daclatasvir Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Daclatasvir Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Daclatasvir Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bristol-Myers Squibb Basic Information And Sales Area

Table 31: Bristol-Myers Squibb. Products Portfolio

Table 32: Natco Pharma Basic Information And Sales Area

Table 33: Natco Pharma. Products Portfolio

Table 34: Zydus Cadila Basic Information And Sales Area

Table 35: Zydus Cadila. Products Portfolio

Table 36: Hetero Drugs Basic Information And Sales Area

Table 37: Hetero Drugs. Products Portfolio

Table 38: Dr Reddy's Laboratories Basic Information And Sales Area

Table 39: Dr Reddy's Laboratories. Products Portfolio

Table 40: Cipla Basic Information And Sales Area

Table 41: Cipla. Products Portfolio

Table 42: Mylan Basic Information And Sales Area

Table 43: Mylan. Products Portfolio

Table 44: Abbott Basic Information And Sales Area

Table 45: Abbott. Products Portfolio

Table 46: Emcure Pharmaceuticals Basic Information And Sales Area

Table 47: Emcure Pharmaceuticals. Products Portfolio

Table 48: Torrent Pharmaceuticals Basic Information And Sales Area

Table 49: Torrent Pharmaceuticals. Products Portfolio

Table 50: Biocon Basic Information And Sales Area

Table 51: Biocon. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Daclatasvir Market Value (USD Million) By Region

Table 57: Global Daclatasvir Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

FAQs

1. What is the current Daclatasvir market size?

The Daclatasvir market size was estimated at USD 1.1 billion in 2023, driven primarily by hepatitis C treatment adoption across North America and Europe. Revenue includes branded and generic sales, with a modest contribution from emerging markets where pricing pressures remain high.

2. What is the projected growth forecast for the Daclatasvir market?

Analysts project the Daclatasvir market to expand at a compound annual growth rate of 5.8% through 2032, reaching roughly USD 1.8 billion. The future outlook is buoyed by combination regimens, expanding screening programs, and increasing reimbursement in high‑income regions.

3. What are the key drivers fueling market expansion?

Key drivers include the drug’s pan‑genotypic efficacy, simplified dosing, and favorable safety profile, which enhance patient adherence. Additionally, government‑backed hepatitis C elimination targets, rising diagnosis rates, and strategic partnerships for generic manufacturing accelerate market penetration worldwide.

4. What challenges could impede market growth?

Challenges comprise high treatment costs in developed economies, patent restrictions limiting generic entry, and competition from newer direct‑acting antivirals offering shorter therapy. Moreover, variable reimbursement policies and limited awareness in low‑income regions constrain broader adoption of Daclatasvir.

5. Which regions lead the Daclatasvir market?

North America remains the largest contributor, driven by premium pricing and robust insurance coverage, followed by Europe where national hepatitis C programs boost sales. Asia‑Pacific shows rapid growth, especially in Japan and China, due to expanding screening initiatives.

6. Who are the top companies operating in this market?

The top players include Bristol‑Myers Squibb, which markets the branded product Daklinza, and Merck KGaA, a key partner for Asian distribution. Generic manufacturers such as Cipla, Natco, and Hetero also capture significant market share in price‑sensitive territories.

7. What future opportunities exist for stakeholders?

Future opportunities arise from developing fixed‑dose combinations that pair Daclatasvir with next‑generation antivirals, expanding into pediatric hepatitis C therapy, and leveraging digital adherence tools. Additionally, emerging markets present untapped demand as national elimination programs mature.

8. How is technology influencing the Daclatasvir market?

Advanced manufacturing technologies, such as continuous flow synthesis, lower production costs and improve scalability, while real‑world evidence platforms generate outcome data that support reimbursement negotiations. Telemedicine also facilitates remote prescription and monitoring, expanding patient access.

9. What is the regulatory landscape for Daclatasvir?

Regulators in the U.S., EU, and Japan have granted full approval for Daclatasvir in combination regimens, while many emerging economies rely on WHO prequalification for generic entry. Ongoing patent litigations and periodic label updates shape the compliance environment.

Contact for Full Report

Loading report content...

Daclatasvir Market Report 2026: Analyst-Verified Data & Forecast

Market Snapshot

Daclatasvir Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Daclatasvir Segmentation

Daclatasvir Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Daclatasvir market size?

2. What is the projected growth forecast for the Daclatasvir market?

3. What are the key drivers fueling market expansion?

4. What challenges could impede market growth?

5. Which regions lead the Daclatasvir market?

6. Who are the top companies operating in this market?

7. What future opportunities exist for stakeholders?

8. How is technology influencing the Daclatasvir market?

9. What is the regulatory landscape for Daclatasvir?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Daclatasvir Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Daclatasvir Segmentation

Daclatasvir Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Daclatasvir market size?

2. What is the projected growth forecast for the Daclatasvir market?

3. What are the key drivers fueling market expansion?

4. What challenges could impede market growth?

5. Which regions lead the Daclatasvir market?

6. Who are the top companies operating in this market?

7. What future opportunities exist for stakeholders?

8. How is technology influencing the Daclatasvir market?

9. What is the regulatory landscape for Daclatasvir?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation